Next-generation ALK inhibitors such as ceritinib (14, 15), alectinib (16, 17), brigatinib (18, 19) have shown effectiveness both in the second-line therapy after progression on crizotinib and in the first-line therapy for ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.